Surgical treatment of small cell lung cancer

Eur J Cardiothorac Surg. 1995;9(2):59-64. doi: 10.1016/s1010-7940(05)80018-1.

Abstract

From 1970 till 1989, 30 patients underwent surgical resection for small cell lung cancer (SCLC). The 5-year survival in stage I patients was 31%, in stage II 17% and in stage III the projected 5-year survival was 9%. Among N2 patients there were only 25% survivors after 1 year and none after 2 years. The first group of 15 patients (1970-1979) received no adjuvant chemotherapy in contrast to the second group of 15 patients (1980-1989). The overall 5-year survival for the first group was 13% and the estimated 5-year survival for the second group was 27%. In stage I SCLC, the 5-year survival was 12% and 60%, respectively. These results confirm that surgery may lead to long-term survival in stage I and possibly stage II SCLC, with better prognosis in stage I when adjuvant chemotherapy is added.

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Carboplatin / therapeutic use
  • Carcinoma, Small Cell / drug therapy
  • Carcinoma, Small Cell / mortality
  • Carcinoma, Small Cell / pathology
  • Carcinoma, Small Cell / surgery*
  • Chemotherapy, Adjuvant
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Etoposide / therapeutic use
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / surgery*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies
  • Survival Rate
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Carboplatin

Supplementary concepts

  • CAV protocol